SCHEMBL7933226

SCHEMBL7933226

CCCCCc1cnc(C(=O)Nc2ccc(F)c(CNc3cccnc3N)c2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 11/20 0.51
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HDAC3 O15379 2/20 0.37
HDAC1 Q13547 2/20 0.37
HDAC2 Q92769 2/20 0.37
VCP P55072 1/20 0.37
BACE2 Q9Y5Z0 3/20 0.36
NCOR1 O75376 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
CYP2D6 P10635 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GRM4 Q14833 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7946658 0.87 BACE1 (0.63) BACE1BACE2CYP2D6KDM4EMAPT
SCHEMBL7941004 0.86 BACE1 (0.54) BACE1NPC1RAB9ASMN1; SMN2HDAC3
SCHEMBL7932671 0.85 BACE1 (0.69) BACE1HDAC3HDAC1HDAC2NCOR1
SCHEMBL7941880 0.85 SMN1; SMN2 (0.57) BACE1NPC1RAB9ASMN1; SMN2BACE2
SCHEMBL12303597 0.84 BACE1 (0.54) BACE1NPC1RAB9ASMN1; SMN2HDAC3
SCHEMBL7944835 0.84 BACE1 (0.54) BACE1NPC1RAB9ASMN1; SMN2HDAC3
SCHEMBL7944837 0.84 BACE1 (0.64) BACE1BACE2CYP2D6
SCHEMBL7945301 0.84 BACE1 (0.62) BACE1BACE2CYP2D6
SCHEMBL7946733 0.83 BACE1 (0.52) BACE1NPC1RAB9ASMN1; SMN2HDAC3
SCHEMBL7941875 0.83 BACE1 (0.73) BACE1BACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885NPC1 431/4885RAB9A 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.